Skip to main content

Table 3 Summary of DVH analysis for OARs

From: Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients

 

Objective

Group A+B

Group C

  

Spinal Cord

D1% [Gy]

46Gy

37.7 ± 6.8 [max 44.2]

22.5 ± 19.8 [max 39.7]

  

Brain Stem

D1% [Gy]

54Gy

25.5 ± 13.0 [max 49.4]

30.2 ± 12.4 [max 48.7]

  

Parotid

Volume [cm3]

 

21 ± 7

24 ± 9

Mean [Gy]

< 26Gy

21.5 ± 6.4 [max 38.2]

14.7 ± 10.2 [max 25.9]

V30Gy [%]

< 45%

24.4 ± 13.7 [max 64.6]

10.5 ± 11.8 [max 26.7]

  

Parotid-PTV

Volume [cm3]

 

20 ± 7

24 ± 10

Mean [Gy]

< 26Gy

19.7 ± 5.6 [max 36.4]

13.8 ± 9.3 [max 25.0]

V30Gy [%]

< 45%

20.4 ± 11.9 [max 61.9]

8.0 ± 8.6 [max 16.8]

  

Oral Cavity

Mean [Gy]

 

28.3 ± 9.8 [max 40.8]

 

V40Gy [%]

< 50%

20.0 ± 15.7 [max 43.2]

 
  

Larynx

Mean [Gy]

 

34.9 ± 6.4 [max 44.3]

 

V40Gy [%]

< 50%

26.6 ± 14.6 [max 42.8]

 
  

Eyes

Mean [Gy]

  

23.5 ± 8.8 [max 43.6]

V40Gy [%]

< 50%

 

10.1 ± 17.5 [max 57.1]

  

Optic Nerves

D1% [Gy]

< 50Gy

 

46.7 ± 6.8 [max 56.3]

  

Chiasm

D1% [Gy]

< 50Gy

 

40.7 ± 9.0 [max 47.4]

  

Healthy tissue

Volume [dm3]

 

12.57 ± 4.56

11.40 ± 6.42

Mean [Gy]

 

6.4 ± 2.9

4.4 ± 2.2

V5Gy [dm3]

 

3.21 ± 1.42

2.36 ± 1.18

V10Gy [dm3]

 

2.45 ± 1.12

1.73 ± 1.00

EI100%

 

0.53 ± 1.26

0.80 ± 0.90

DoseInt [Gy dm3]

 

72.87 ± 25.23

42.78 ± 26.02

  1. Dx% = dose received by the x% of the volume; Vx% = volume receiving at least x% of the prescribed dose; CI = ratio between the patient volume receiving at least 95% of the prescribed dose and the volume of the total PTV. DoseInt = Integral dose, [Gy cm3 103]